Tumor microenvironment immune types (TMIT) have been classified into four categories, with cervical cancer specified as TIMT I with high expression of PD-L1 and CD8A/cytolytic activity (CYT), according to the classification criteria of TMIT by expression of PD-L1 and CD8A/CYT. This evidence concerns the gene CD8A and cervical carcinoma.